HIV vaccine for adults may be on its way after a vaccine was
administered on monkeys with an HIV-like virus, especially in light
of a new, weakened version of it proved to offer similar protections
from the original version.
the Science Translational Medicine journal, published July 17, papers
were written that highlight how the attenuated vaccine was weakened
so the herpes virus cytomegalovirus could not be easily spread. The
new vaccine version was able to get rid of SIV (monkey HIV) in 59
percent of the animals.
result was similar to findings that involved the non-attenuated,
initial version. The attenuated vaccine also improved the immunity
in nine of the 12 monkeys, as they were still battling against the
SIV infection three years after the injection.
an attenuated version of this vaccine, there is a chance for it being
used on humans. There are no vaccines with non-attenuated live
viruses because of safety issues. Humans with non-complicated CMV may
find that a virus can cause problems in people who have a weakened
immune system (organ transplant patients). Pregnant women are also at
risk because of the dangers of congenital defects such as
microcephaly and hearing loss.
to Dr. Klaus Fruh, an OHSU Vaccine and Gene Therapy Institute
professor, the research offers some good insights into the
development of human CMV-based HIV vaccine. With attenuated CMV, this
version offered the same kind of immune responses as the vaccine’s
new work shows that most vaccinated rhesus masques were protected
against SIV, and the initial vaccine continued to work for years
afterward. Fruh said it was a strength of durability that could pave
the way for human HIV vaccine.
Vir Biotechnology, Inc. has licensed the CMV vaccine, and it plans to set up a clinical trial for a human type of CMV-based HIV vaccine. The platform will also be used to develop a tuberculosis vaccine.